A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Latest Information Update: 30 May 2025
At a glance
- Drugs ZW 191 (Primary)
- Indications Endometrial cancer; Gynaecological cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Zymeworks
Most Recent Events
- 08 May 2025 According to a Zymeworks media release, the company plans to present trial-in-progress poster at the American Society of Clinical Oncology annual meeting on June 2, 2025
- 05 Mar 2025 According to a Zymeworks media release, recruitment in the dose escalation portion of the study remains ongoing.
- 05 Nov 2024 According to a Zymeworks media release, company announced that the first patient has been dosed in this trial.